Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719077 | 0.92 | SMN1; SMN2 (0.62) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL6341570 | 0.84 | TLR9 (0.52) | KMT2AMAPTMEN1SMN1; SMN2HPGD | |
| SCHEMBL11645186 | 0.82 | KMT2A (0.59) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL8747045 | 0.80 | HPGD (0.49) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL8114562 | 0.79 | KMT2A (1.00) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL718093 | 0.76 | MAPT (0.52) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL31717926 | 0.76 | MAPT (0.60) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL5479900 | 0.76 | MAPT (0.60) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL10983420 | 0.76 | MGLL (0.62) | KMT2AMAPTMEN1MGLLSMN1; SMN2 | |
| SCHEMBL137793 | 0.76 | MGLL (1.00) | KMT2AMAPTMEN1MGLLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108587927-B | (S)-selectivity organism catalyst | 中山大学 | 2019-08-09 | — | — | CN | claimed |
| CN-108611281-B | One plant of marine source aspergillus sydowii and application thereof | 中山大学 | 2019-07-23 | — | — | CN | claimed |
| CN-108611281-A | One plant of marine source aspergillus sydowii and application thereof | 中山大学 | 2018-10-02 | — | — | CN | claimed |
| CN-108587927-A | (S)-selectivity organism catalyst | 中山大学 | 2018-09-28 | — | — | CN | claimed |
| WO-2014031594-A2 | MODULATING VOLTAGE-OPERATED CALCIUM CHANNELS ON IMMUNE CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| WO-2005086971-A2 | ANTI-METASTATIC ABILITY OF MIBEFRADIL AND GADOLINIUM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-09-22 | — | — | WO | claimed |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CAVION, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11273218-B2 | Methods for treating Angelman syndrome and related disorders | CAVION, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CAVION, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200163943-A1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3615521-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | Cavion, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615010-A1 | METHODS FOR TREATING DRAVET SYNDROME | Cavion, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| CN-110799215-A | Methods of treating Dravet syndrome | 卡维昂公司 | 2020-02-14 | — | — | CN | disclosed |
| WO-2017070680-A1 | METHODS FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | CAVION LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-1613420-B1 | METHOD FOR SELECTIVELY BINDING A SUBSTRATE TO SORBENTS BY WAY OF AT LEAST BIVALENT BONDS | INSTRACTION GMBH (DE) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014031594-A2 | MODULATING VOLTAGE-OPERATED CALCIUM CHANNELS ON IMMUNE CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-1613420-A2 | METHOD FOR SELECTIVELY BINDING A SUBSTRATE TO SORBENTS BY WAY OF AT LEAST BIVALENT BONDS | instrAction GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| US-20060003020-A1 | Anti-metastatic ability of mibefradil and gadolinium | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005086971-A2 | ANTI-METASTATIC ABILITY OF MIBEFRADIL AND GADOLINIUM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2004085046-A2 | METHOD FOR SELECTIVELY BINDING A SUBSTRATE TO SORBENTS BY WAY OF AT LEAST BIVALENT BONDS | INSTRACTION GMBH (DE) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163943-A1 | METHODS FOR TREATING DRAVET SYNDROME | CACNA1G, CACNB2, CACNA1H | KMT2A 1058/4885MAPT 217/4885MEN1 684/4885 |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CACNA1G, CACNA1I, CACNA1H | KMT2A 910/4885MAPT 56/4885MEN1 1587/4885 |
| US-11273218-B2 | Methods for treating Angelman syndrome and related disorders | CACNA1G, CACNA1I, CACNA1H | KMT2A 774/4885MAPT 1876/4885MEN1 700/4885 |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CACNA1G, CACNA1I, CACNA1H | KMT2A 910/4885MAPT 56/4885MEN1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.